SynAct Pharma reports positive PK data on AP1189 tablets
SynAct Pharma AB ("SynAct") today announced that it has received positive data from the first part of the ongoing pharmacokinetic (PK) study of AP1189 following oral administration of AP1189 tablets to healthy volunteers.Data from a single dose cross-over study in 12 healthy volunteers of dosing of 2 x 50 mg AP1189 Tablets vs 100 mg AP1189 Powder for Suspension (the formulation used in the current clinical phase 2 development program), demonstrates that relevant PK parameters are comparable following dosing tablets and oral suspension. The data supports use of tablets in upcoming clinical